Back
Journey Medical 10K Form
Sell
49
DERM
Journey Medical
Last Price:
5.30
Seasonality Move:
-2.31%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-05-14 | 10Q | DERM/Journey Medical Quarterly |
2023-11-13 | 10Q | DERM/Journey Medical Quarterly |
2023-08-10 | 10Q | DERM/Journey Medical Quarterly |
2023-05-22 | 10Q | DERM/Journey Medical Quarterly |
2022-11-10 | 10Q | DERM/Journey Medical Quarterly |
2022-08-09 | 10Q | DERM/Journey Medical Quarterly |
Receive DERM News And Ratings
See the #1 stock for the next 7 days that we like better than DERM
DERM Financial Statistics
Sales & Book Value
Annual Sales: | $79.18M |
---|---|
Cash Flow: | $-1.16M |
Price / Cash Flow: | 0 |
Annual Sales: | $0.53 |
Price / Book: | 10.27 |
Profitability
EPS (TTM): | -0.94000 |
---|---|
Net Income (TTM): | $-18.34M |
Gross Margin: | $52.52M |
Return on Equity: | -125.77% |
Return on Assets: | -27.08% |
Journey Medical Earnings Forecast
Key Journey Medical Financial Ratios
- The Gross Profit Margin over the past 5 years for DERM is 66.33%.
- The Selling, General & Administrative Expenses for DERM have been equal to 55.46% of Gross Profit Margin.
- The Research & Development expenses have been 9.52% of Revenue.
- The Interest Expense is -44.07% of Operating Income.
- The Net Earning history of DERM is -4.87% of Total Revenues.
- Per Share Earnings over the last 5 years have been positive in 3 years.
Journey Medical Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Pharmaceuticals |
Sector: | Health Care |
Current Symbol: | DERM |
CUSIP: | 24983L |
Website: | journeymedicalcorp.com |
Debt
Debt-to-Equity Ratio: | 1.81 |
---|---|
Current Ratio: | 1.38 |
Quick Ratio: | 0.99 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
DERM Technical Analysis vs Fundamental Analysis
Sell
49
Journey Medical (DERM)
is a Sell
Is Journey Medical a Buy or a Sell?
-
Journey Medical stock is rated a Sell
The current Journey Medical [DERM] share price is $5.37. The Score for DERM is 49, which is 2% below its historic median score of 50, and infers higher risk than normal.